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Abstract
Malaria remains a major threat to human health, as strains resistant to current therapeutics
are discovered. Efforts in finding new drug targets are hampered by the lack of sufficiently
specific tools to provide target validation prior to initiating expensive drug discovery projects.
Thus, new approaches that can rapidly enable drug target validation are of significant
interest.
In this manuscript we present the crystal structure of malate dehydrogenase from Plas-
modium falciparum (PfMDH) at 2.4 Å resolution and structure-based mutagenic experi-
ments interfering with the inter-oligomeric interactions of the enzyme. We report decreased
thermal stability, significantly decreased specific activity and kinetic parameters of PfMDH
mutants upon mutagenic disruption of either oligomeric interface. In contrast, stabilization of
one of the interfaces resulted in increased thermal stability, increased substrate/cofactor
affinity and hyperactivity of the enzyme towards malate production at sub-millimolar sub-
strate concentrations. Furthermore, the presented data show that our designed PfMDH
mutant could be used as specific inhibitor of the wild type PfMDH activity, as mutated
PfMDH copies were shown to be able to self-incorporate into the native assembly upon
introduction in vitro, yielding deactivated mutant:wild-type species. These data provide an
insight into the role of oligomeric assembly in regulation of PfMDH activity and reveal that
recombinant mutants could be used as probe tool for specific modification of the wild type
PfMDH activity, thus offering the potential to validate its druggability in vivo without recourse
to complex genetics or initial tool compounds. Such tool compounds often lack specificity
between host or pathogen proteins (or are toxic in in vivo trials) and result in difficulties in
assessing cause and effect—particularly in cases when the enzymes of interest possess
close homologs within the human host. Furthermore, our oligomeric interference approach
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gen drug targets.
Introduction
Malaria is a devastating disease and Plasmodium falciparum is responsible for the most lethal
form of malaria [1]. During proliferation of the parasite within the host’s red blood cell the
parasite depends on external nutrients that have to be imported and subsequently metabolized
[2, 3]. This interconversion of nutrients is believed to be essential to provide the metabolic
intermediates for the parasite’s growth. The validation of the druggability of these metabolic
steps is highly challenging as the applicability of the probe techniques is limited in P. falcipa-
rum and depends on reverse genetics [4]. However, a possible alternative is offered through
the examination of interaction surfaces between subunits of oligomeric proteins.
In recent publications Panchenko and colleagues summarised the biological importance,
physico-chemical properties and evolutionary aspects of protein oligomerisation [5–7]. The
authors showed that approximately 60% of the non-redundant protein structures available
in the Protein Data Bank (PDB) are of dimeric or higher oligomeric order [6]. Protein oligo-
merisation is a feature shared by all organisms; oligomerisation is often essential to form func-
tional protein complexes and can provide regulatory, stability, protective, selective, functional
diversity or evolutionary benefits to the host organism [7]. Oligomeric interfaces also show
extremely high specificity and binding affinity. In the majority of cases, oligomeric proteins
can be purified from both recombinant and native sources in a single oligomeric state that
show no non-cognate incorporation within the isolated assembly. Specificity of the oligomeric
interfaces minimizes the interactions between unwanted partners, such as closely related and
similar proteins of different pathways. Disruption of the native oligomeric state of the protein
also often leads to the misregulation or the complete loss of function. Nishi and colleagues
have shown a number of examples where mutations induce changes in the native oligomeric
state, leading to devastating human diseases such as Alzheimer [7].
The evolutionary diversity of protein:protein interaction interfaces is also a key parameter
in the study and treatment of infectious diseases. In many cases the proposed target protein
from a pathogen shares function with a homologous protein of the human host. Tool com-
pounds or methods that target the likely conserved active sites of the pathogenic enzymes will
almost inevitably interact with the homologous proteins of the host system, as evolutionary
constraints will restrict sequence diversity in these regions. Protein:protein interaction surfaces
are less restricted by such constraints, as compensatory mutations can return the function of
the surface (supporting oligomerisation) more diversely than mutations in an active site that
must retain molecular function. This evolutionary diversity is also found in protein:protein
interactions within oligomeric protein assemblies. Earlier studies have shown that protein
interfaces tend to exhibit slightly higher level of evolutional conservation than the rest of the
surface [8, 9] but significantly lower than that of active sites. Thus, we believe that oligomeric
surfaces offer a potential in selective incorporation that may rival current cutting-edge genetic
approaches to validate essential pathways for their druggability.
Enzymes within plasmodial carbon metabolism pathway have previously been suggested as
promising targets for drug discovery [10, 11]. Particularly, our previous research was focused
on plasmodial aspartate aminotransferase (PfAspAT, EC 2.6.1.1), an enzyme involved in
aspartate metabolism, energy metabolism, pyrimidine biosynthesis as well as supplying the
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TCA cycle of the parasite with it’s intermediates [12–14]. Malate dehydrogenase (PfMDH, EC
1.1.1.37) is located downstream of PfAspAT in the cytosol of the parasite. It catalyzes the
reversible reaction from malate to oxaloacetate using the reduction of NAD+ to NADH, thus
aiding in the maintenance of the correct redox environment, crucial for the parasite’s survival
particularly during the blood stages [15]. PfMDH is also involved in the shuttle mechanism of
the TCA cycle intermediates (malate/oxaloacetate), necessary for electron transfer from cyto-
solic NADH to the mitochondrial electron transport chain [16], a validated antimalarial drug
target [17, 18]. These data make PfAspAT as well as PfMDH promising antimalarial drug
targets.
Recently, the crystal structure of the PfAspAT has been solved [13] and PfMDH has been
biochemically characterized and its spatial structure has been modeled [19–22]. Pradhan and
colleagues reported a number of mutagenic experiments aimed at identification and character-
ization of key substrate and co-substrate binding pockets of PfMDH [21]. Furthermore, based
on their in silico model authors reported analysis of the quaternary structure of PfMDH as
well as attempts to disrupt its oligomeric assembly [20]. Despite these efforts, neither PfAspAT
nor PfMDH has as yet been validated as a drug target. In both cases (as well as in case of other
malarial enzymes that possess close homologs in human host) an inhibition tool with sufficient
specificity in vivo is needed for successful drug target validation.
Here we report the crystal structure of PfMDH at 2.4Å resolution. Based upon an examina-
tion of the crystal structure we have identified two major oligomeric interfaces within the tet-
ramer and designed two point mutations (E18W and V190W) aiming at disruption of these
interfaces. As anticipated, both mutations distorted the native oligomeric state, resulting in
dimeric species with alternated kinetic parameters and significantly reduced specific activity.
No evidence of significant misfolding could be derived, as both mutants retained basal activity
and the ability to bind to oxaloacetate and cofactor NADH. Alternatively, introduction of
additional hydrogen bonds via the E18Q mutation has likely stabilized the respective interface
and resulted in increased specific activity of the enzyme (malate formation) at sub-millimolar
substrate concentration.
Furthermore, our co-purification experiments showed that deactivated PfMDH-V190W
species were able to incorporate into the native PfMDH assembly in vitro. The resulting chi-
meric protein contained both wild type and mutant copies, as confirmed by western blotting,
and possessed no measurable activity.
These findings show that interference with oligomeric interfaces of PfMDH could be used
to modulate its function with high specificity. The structural information on PfMDH has been
used to generate recombinantly expressed mutant protein that could incorporate into the
native assembly, inhibiting the specific activity in vitro. Extension of such a method in vivo
could be used as a general tool approach in drug target validation, especially in challenging
cases where the active site of the target protein is highly conserved or no tool compound with
sufficient specificity is available.
Results
Wild-type malate dehydrogenase (EC 1.1.1.37) from Plasmodium falciparum (PfMDH-WT)
was cloned, recombinantly expressed, purified and crystallised, as previously described [23].
PfMDH-WT crystals belonged to P1 space group and diffracted to 2.4 Å. Molecular replace-
ment yielded a clear solution of 4 tetramers in the asymmetric unit with R/Rfree of 0,25/0,26,
respectively (Table 1). The final model has been deposited in PDB under accession code
5NFR. PfMDH is a globular tetrameric protein [20, 23], where each monomer is comprised of
326 residues, which form 9 alpha helixes and 11 beta-sheets (Fig 1a and 1b). Similarly to other
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NAD-dependent dehydrogenases, the active sites are located in the cleft between two domains:
an N-terminal cofactor-binding domain containing a parallel structure of first six beta-sheets
(Rossmann-fold) and C-terminal substrate-binding domain (Fig 1a) [21, 24].
Overall, PfMDH shows high structural homology with other apicomplexian dehydroge-
nases available in the PDB [25]. When superposed with a structure of a predicted ancestral api-
complexian malate dehydrogenase (4PLH) [26], PfMDH structure shows an rmsd on C-alpha
positions of approx. 1 Å (Fig 1c). Similarly, superposition with Cryptosporidium parvum MDH
(2HJR) [27] shows an rmsd of 1.3 Å (Fig 1d). Subsequently, sequence conservation of PfMDH
amongst closely homologous species was analyzed using BLAST [28]. Overall, the residues of
PfMDH showed a sequence conservation of 32% amongst this set of closest relatives, with the
residues comprising the active sites possessed a sequence conservation of close to 100%
Table 1. Data collection and refinement statistics of PfMDH.
PfMDH (5NFR)
Data collection
Beamline X13 (EMBL) BM14 (ESRF)
Space group P1 P1
Cell dimensions:
a, b, c (Å) 71.8, 156.6, 158.6 72.02, 152.69, 158.39
α, β, γ (o) 104.6, 101.1, 95.1 103.77, 101.46, 94.93
Resolution (Å) 19.76–2.95 47.6–2.4
Rmerge 17.6 (64.8) 5.3 (45.6)
Mean I/σI 5.88 (1.42) 10.46 (1.57)
Completeness (%) 92.0 (73.6) 89.5 (64.3)












Bond lengths (Å) 0.019
Bond angles (˚) 1.743
Ramachandran plot:
Most favored, % 97.40
Allowed, % 2.27
R-factor is defined as (Shkl|Fobs(hkl) − Fcalc(hkl)|)/Shkl Fobs (hkl), where Fobs and Fcalc are observed and calculated
structure factors of the reflection of hkl, respectively.
Rmerge is defined as Shkl Si | Ii(hkl) −< I(hkl) > | / Shkl Si Ii(hkl), where Ii(hkl) is the ith intensity measurement of
reflection hkl and <I(hkl)> is the average intensity from multiple observations.
Rfree was calculated on the basis of a small subset (5%) of randomly selected reflections omitted from the refinement.
Values in parentheses correspond to the highest resolution shell. Data collection statistics are derived from previously
reported article [23]
https://doi.org/10.1371/journal.pone.0195011.t001
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Fig 1. Fig 1 (a) shows the secondary structure of wild type PfMDH as well as substrate and cofactor binding sites. Like other malate dehydrogenases, PfMDH
consists of 9 alpha-helixes and 11 beta-sheets. First 6 beta-sheets form parallel structure (Rossman fold) and belong to the cofactor-binding N-terminal domain.
The NADH and pyruvate molecules were modeled using superposition with homologous MDH structure (4PLC, rmds 1 Å) [26]. (b) PfMDH is a globular homo-
tetramer, the subunits are labeled A, B, C and D. (c) Structural superposition of PfMDH (green) with predicted ancestral apicomplexian malate dehydrogenase
(53% sequence identity, 1 Å rmsd on C-alphas, 4PLC) [26] shown in magenta. (d) Structural superposition of PfMDH (green) with MDH from Cryptosporidium
parvum (43% sequence identity, 1.3 Å rmsd on C-alphas, 2HJR) [27] used for molecular replacement (cyan). Structures were superimposed using GESAMT [48]
package from CCP4 suite [44] and visualized using PyMol [49].
https://doi.org/10.1371/journal.pone.0195011.g001
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(Table 2). The analysis of the oligomeric interfaces as measured by PISA [29] online server,
revealed an total solvent accessible surface area of 3641 Å2 (25% of the total accessible surface
area) where 15.8% of the residues are conserved (Table 2).
The oligomeric surfaces of PfMDH can be split into two major groups: AB and AC (Fig 2a
and 2b, Table 2). These surfaces comprise 1852.9 Å2 (AB) and 1372.1 Å2 (AC), respectively.
The smaller interface (AD) likely does not represent a surface essential for oligomerization due
to its relatively small size (421.3 Å2) and we have neglected it in the current analysis. Overall,
15.8% of the surface residues are conserved amongst the closest relatives. These observations
agree with earlier reports, which show that in general enzyme oligomeric surfaces show signifi-
cantly lower conservation than active site residues [8, 9]. Active sites from subunits A and B
mirror each other and are located in close proximity to the AB interface (but well separated
from each other and interface residues) (Fig 2d) and distal to the AC interface. The AB
PfMDH sub-assembly is highly similar to other dimeric malate dehydrogenases, such as E. coli
MDH (29% sequence identity, 2.5 Å rmsd, 2PWZ, primary citation unavailable) (Fig 2e).
Structural comparison with Human type 2 MDH (28% identity; 2DFD, primary citation not
available) shows a lower degree of structural homology between the separate subunits of each
tetramer (2.5 Å rmsd on C-alphas).
Point mutations influence the oligomeric state of PfMDH
Based upon an examination of the crystal structure, point mutations of PfMDH were designed
to interfere with the AB and AC oligomeric surfaces. The loop region between α6 and β8 of
Table 2. Sequence conservation of PfMDH across homologs and surface analysis.
PfMDH (5NFR)
No. of residues 313
Conserved residues
(% of total number of residues)
99 (31.6%)
 absolutely 24 (7.7%)
: strongly 42 (13.5%)
. weakly 33 (10.5%)
Active site residues
(% of active site residues)
6
 absolutely 5 (84%)
: strongly 1 (16%)
. weakly 0
Interface AB AC AD Total
Interface residues 51 37 13 101
Conserved residues 11 (21.7%) 4 (10.8%) 1 (7.7%) 16 (15.8%)
 absolutely 6 (11.7%) 0 0 6 (5.9%)
: strongly 3 (5.9%) 3 (8.1%) 1 (7.7%) 7 (6.9%)
. weakly 2 (3.9%) 1 (2.7%) 0 3 (2.9%)
Total ASA per monomer (Å2) 14290
Interface AB AC AD Total
Buried ASA (% of total ASA), Å2 1852.9 (13.0%) 1372.1 (9.6%) 421.3 (2.9%) 3641 (25.5%)
A table indicating the sequence conservation across the different oligomeric interfaces of PfMDH. Sequence conservation of PfMDH amongst closely homologous
species was analyzed using BLAST (4). Overall, the residues of PfMDH show a sequence conservation of 31.6% amongst this set of closest relatives, while the residues
comprising the active sites possessed a sequence conservation of 84% (Fig 1b, 1e and 1f). Analysis of the oligomeric interfaces using PISA [29] revealed an overall
oligomeric surface of 3641 Å2, with contributions to the different oligomeric interfaces as shown above.
https://doi.org/10.1371/journal.pone.0195011.t002
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each subunit (residues 187–192) was found reaching in the hydrophobic pocket region
between β7 and β10 of adjacent subunit, facilitating the AC oligomeric contact (Fig 3a). The
mutation V190W was designed to introduce a steric clash (Fig 3a) in that region of AC inter-
face—potentially resulting in a dimeric form of PfMDH similar to that observed in other
organisms (e.g. E. coli; Fig 2e). The PfMDH-V190W mutant was recombinantly expressed and
purified. The impact of the mutations was confirmed by static light scattering measurements
Fig 2. Figs 2 a-c show the interfaces formed between individual subunits of PfMDH: AB (a), AC (b) and AD (c); residues involved in the oligomeric contact are
shown in blue. Evolutionary conservation of the interface residues is shown in red (absolutely conserved), orange (strictly conserved) and green (slightly
conserved). For more details on sequence conservation please refer to Table 2. (d) Positions of the active sites of adjacent subunits A (yellow) and B (Magenta) are
shown. Active sites from A and B subunits are mirror reflections of each other, well separated and distal to AC interface. (e) Structural superposition of PfMDH
AB subassembly (green) and dimeric malate dehydrogenases from E. coli MDH (29% sequence identity, 2.5 Å rmsd, 2PWZ, primary citation unavailable) shown in
gold. In order to highlight the active site positions, the NADH and pyruvate molecules were modeled into the active sites using superposition with homologous
MDH structure (4PLC, rmds 1 Å) [26]. Structure superposition was performed using GESAMT [48] package from CCP4 suite [44] and visualized using PyMol
[49].
https://doi.org/10.1371/journal.pone.0195011.g002
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(Table 3), confirming that PfMDH-V190W is dimeric in solution. These results have sug-
gested that the mutation had the desired effect of disrupting the AC interface and that the AB
interface in V190W mutant remained unperturbed, as this interface could still support
dimerization.
Fig 3. Fig 3. (a-top) Undisrupted oligomeric interface of PfMDH (AC). Subunit A is schematically shown as cartoon (yellow), surface of the adjacent subunit C is
shown in cyan. (a-bottom) Interface mutation V190W located between α6 and β8 causes disruption of the A-C interface as confirmed by SLS experiments. Point
V190W mutations were modeled in PfMDH structure using Coot [46] and visualized using PyMol [49]; mutated clashing residues are shown in red. (b-top) Native
AB oligomeric interface of PfMDH; Glutamate 18 pair in the core α1:α1 is shown in sticks. (b-bottom) Predicted steric clash caused by E18W mutation, causing an
oligomeric disruption of AB interface and a model of the additional hydrogen bond pair (Gln18-Gln18) introduced between α1 helixes from adjacent subunits.
https://doi.org/10.1371/journal.pone.0195011.g003
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The AB interface is mainly formed by residues that belong to alpha helixes 1, 2, 5 and 8
from both subunits. The core non-conserved region between the α1 helixes of each subunit is
mainly hydrophobic with the exception of the acidic Glu 18 pair (Fig 3b). Similarly to the
V190W case, a point mutation E18W was designed to introduce a steric clash between the sub-
units A and B (Fig 3b). PfMDH-E18W mutant was recombinantly expressed, purified and
subsequently characterized using SLS measurements (Table 3), confirming the presence of
dimeric species.
The E18Q mutation was designed to strengthen the AB interface by replacing the Glu:Glu
interaction with complementary hydrogen bonding pair between the mutated glutamines 18
from adjacent chains (Fig 3b). Similarly, PfMDH-E18Q was recombinantly expressed and
purified. The ability of the PfMDH-E18Q mutant to form tetramers in vitro, as confirmed by
SLS (Table 3), strongly suggests that there were no adverse alterations to the surfaces that sup-
port oligomerisation (either AB or AC).
Thermal stability of PfMDH interface mutants indicates the mutants adopt
a well-folded conformation
Purified PfMDH WT as well as the mutant samples were assayed against a buffer-component
library using thermal shift assay (TSA) [30–32]. Interestingly, all PfMDH samples were rather
unstable at physiological conditions (in PBS, Fig 4a), agreeing with previously reported sharp
thermal transition and activity loss in the range of 313–318 K observed for PfMDH, purified
directly from P. falciparum parasites [22]. Taken together these data the buffer conditions for
Table 3. Summary of the biophysical parameters of PfMDH mutants, as assessed by Static Light Scattering assay (SLS), Microscale Thermophoresis assay (MST)
and Thermal Shift Assay (TSA).
PfMDH Wild type V190W E18W E18Q
Static Light Scattering (SLS)
Oligomeric state Tetramer Dimer Dimer Tetramer
Molecular weight (kDa) 140.5 ± 4.2 70.5 ± 0.3 76.6 ± 0.4 139.4 ± 0.2
Microscale Thermophoresis (MST)
Dissociation constants:
Oxaloacetate& 3.93 ± 0.58 mM 3.86 ± 0.80 mM 621 ± 220 μM 823 ± 33 μM
Malate& Nd Nd Nd Nd
NADH£ 172 ± 73 μM 474 ± 105 μM 1.66 ± 0.61 mM 3.2 ± 1.2 μM
NAD+ £ Nd Nd Nd Nd
Thermal Shift Assay (TSA)
Samples Tm (ΔTm compared to Assay Buffer sample), K
Assay Buffer 331 315 320 333.5
Oxaloacetate (20 mM) 331 (0) 316 (1) 319 (-1) 333.5 (0)
Malate (20 mM) 333 (2) 316 (1) 318 (-2) 333.5 (0)
NADH (10 mM) 341 (10) 322 (7) 326 (6) 341 (7.5)
NAD+ (10 mM) 334 (3) 318 (3) 319 (-1) 335,5 (0)
& Assays performed in the absence of co-factors
£ Assays performed in the absence of substrates
 in Assay Buffer (100 mM Na-Phosphate pH 7.4 and 400 mM Na Cl)
Oligomeric state determination of the PfMDH WT and its mutants was performed using static light scattering (SLS), as described in Materials and Methods section.
Dissociation constants for NAD and Malate could not be determined for either WT or mutant versions of PfMDH even at high substrate/cofactor concentrations
reaching 20 mM. TSA experiments performed in the Assay buffer (100 mM Na-Phosphate pH 7.4, 400 mM NaCl) assessed the effects of 20 mM oxaloacetate, 20 mM
malate, 10 mM NADH and 10 mM NAD+ on thermal stability of PfMDH and its mutants.
https://doi.org/10.1371/journal.pone.0195011.t003
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further assays have been optimized. Among tested buffer components, 100 mM Na-citrate pH
5.5 and 400 mM NaCl showed highest midpoints of the melt curves (interpreted as Tm, Fig 4).
As a result of TSA analysis the Assay Buffer used for further experiments consisted of 100 mM
Na-phosphate and 400 mM NaCl at pH 7.4. Citrate was not used in the Assay Buffer due to the
annotated activation behavior of citrate on MDH activity [33]. Possible effects of acidic as well
as citrate-based buffer systems on PfMDH have not been addressed in this study. Increased
melting temperatures of PfMDH-WT (ΔTm = 13 K), V190W (ΔTm = 7 K), E18W (ΔTm = 5 K)
Fig 4. Fig 4 shows examples of TSA melting curves of PfMDH WT (dark bold lines), PfMDH-V190W (dotted red lines), PfMDH-E18W (dotted blue lines)
and PfMDH-E18Q (faint lines) in various buffer conditions: (a) PBS, (b) 400 mM NaCl, (c) 100 mM Na-Citrate pH 5.5 and (d) Assay Buffer (100 mM Na-
Phosphate pH 7.4, 400 mM NaCl). Melting temperatures of each sample are displayed next to the respective curves. Analysis of these curves shows that PfMDH is
rather unstable in PBS (a) and requires optimized buffer conditions for further experiments. This effect is more pronounced for its mutant forms, where native
oligomeric assembly has been disrupted (dotted lines). PfMDH-E18Q mutant shows higher thermal stability, thus supporting the hypothesis that introduction of
the additional hydrogen bond pair at the AB interface has had the desired stabilization effect. (b) 400 mM NaCl has significantly stabilized the wild type PfMDH
(ΔTm = 10 K), dimeric V190W mutant (ΔTm = 7 K) and tetrameric E18Q mutant (ΔTm = 8.5 K), while having minor effect of the E18W dimeric mutant (ΔTm = 2.5
K). (c) 100 mM Na-Citrate pH 5.5 significantly stabilized the wild type enzyme (ΔTm = 17.5 K) and the E18Q mutant (ΔTm = 15.5 K), while having lesser effect on
V190W mutant (ΔTm = 6 K) and negligible effect on E18W (ΔTm = 0.5 K). (d) Selection of the Assay Buffer allowed further experiments to be performed for all
four PfMDH constructs used in this study in the same stabilizing buffer conditions (WT ΔTm = 13 K, V190W ΔTm = 7 K, E18W ΔTm = 5 K, E18Q ΔTm = 12.5 K).
TSA assays were performed in 96-well PCR plates (VWR) using SFX96 Real-Time PCR reactor (BioRad). Melting curve (in terms of increased fluorescence, RFU)
of each sample was plotted against the temperature gradient (293–363 K) using BioRad SFX96 software and the temperatures of the inflection points (Tm’s) were
used as indicators of the thermal stability of each sample. ΔTm’s reflect stabilization effect of each condition compared to the control experiments performed in
PBS. For more details refer to Materials and Methods section.
https://doi.org/10.1371/journal.pone.0195011.g004
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and E18Q (ΔTm = 12.5 K) samples in the Assay Buffer compared to PBS allowed the use of
Assay Buffer for all four PfMDH samples in further experiments.
Little or no stabilization effect was observed upon addition of 20 mM substrate (malate or
oxaloacetate) to the Assay Buffer for all four PfMDH samples (Table 3). However, the samples
were significantly stabilized upon addition of 10 mM NADH cofactor (ΔTm 6–10 K). Addition
of other cofactor, NAD+ caused little or no effect on thermal stability of PfMDH wild type and
mutant samples (Table 3).
Interestingly, but not unexpectedly, disruption of the native oligomeric interface in case of
both V190W and E18W resulted in significantly reduced thermal stability (Tm’s approximately
10–15 K lower, Fig 4, Table 3) compared to the wild type enzyme. The PfMDH-V190W
mutant in which the AC interface was disrupted retained the preference for lower pH citrate
buffer (ΔTm = 6 K, Fig 4c) and high ionic strength (ΔTm = 7 K, Fig 4b). Unlike V190W, E18W
mutation disrupting the AB oligomeric interface resulted in significantly less stable enzyme
species inert to either citrate (ΔTm = 0.5 K) or high ionic strength (ΔTm = 2.5 K)(Fig 4b and
4c). As anticipated, E18Q mutation introducing an additional hydrogen bond pair into the AB
interface resulted in mild stabilization of the enzyme (ΔTm = 1–3 K, Fig 4, Table 3).
Overall these data indicate that all PfMDH mutants adopted a folded conformation, in
which the hydrophobic core of the protein is shielded from the bulk solvent, as all three
mutants demonstrated TSA-determined Tm’s consistent with globular proteins, rather than
denatured or unfolded proteins [32, 34]. The reduction in stability of PfMDH-V190W and
PfMDH-E18W mutants compared to the wild type could be attributed to the stabilizing effects
of tetramer assembly upon the individual monomer folds. Relatively high initial fluorescence
signal observed for V190W and E18W samples (Fig 4) compared to the wild type enzyme
could be explained by exposure of hydrophobic parts of AB and AC interfaces, usually shielded
from the solvent, to the SYPRO orange dye.
Oligomeric distortions influence the substrate/cofactor binding of PfMDH
Microscale Thermophoresis (MST, Nanotemper GmgH) experiments performed with fluores-
cently labeled (see Materials&methods) PfMDH-WT supported previously proposed mecha-
nism, where the cofactor NADH/NAD+ must bind prior the substrate [24]. Indeed, the affinity
measured for NADH binding (172 ± 73 μM, Table 3) was much higher that that of substrate
oxaloacetate (3.9 ± 0.6 mM, Table 3). Distortion of the AC interface (distal from the active
sites) via V190W mutation caused 3-fold decreased affinity (Kd 474 ± 105 μM) towards
NADH and no apparent change in oxaloacetate binding (Kd 3.9 ± 0.8 mM). In contrast, AB
interface distortion via E18W mutation resulted in 10-fold decreased NADH affinity (1.7 ± 0.6
mM) and unexpectedly 6-fold increased affinity towards oxaloacetate (0.62 ± 0.22 mM).
Stabilization of the AB interface via E18Q mutation resulted in significantly increased bind-
ing affinity towards both NADH and oxaloacetate (Kd’s 3.2 ± 1.2 μM and 823 ± 33 μM, respec-
tively; Table 3). Binding assays with substrates were performed separately. No measurable
binding of NAD+ or malate could be observed for all PfMDH constructs, supporting previous
hypothesis that under standard conditions the reaction is more favorable towards malate for-
mation [24].
Oligomeric distortions influence the specific activity of PfMDH
Specific activity of the wild type PfMDH and its mutants was measured in terms of amount of
NADH oxidized or (NAD+) reduced (U = 1 μmol NADH min-1) per milligram of the enzyme.
Wild type PfMDH displayed Michaelis-Menthen kinetics for forward reaction (malate oxida-
tion) with Vmax of 9.2 ± 0.4 U mg-1 and Km of 3.0 ± 0.3 mM of malate (Fig 5a). Reverse reaction
Oligomeric interfaces may provide an opportunity to validate drug targets
PLOS ONE | https://doi.org/10.1371/journal.pone.0195011 April 25, 2018 11 / 22
(oxaloacetate reduction) was interpreted as positively cooperative with Hill coefficient of
1.75 ± 0.11, significantly higher Vmax of 111 ± 4 U mg-1 and Khalf of 2.8 ± 0.2 mM (Fig 5b).
These data are consistent with previously reported specific activity of PfMDH measured to be
approx. 80 U mg-1 and no observed substrate inhibition at high oxaloacetate concentrations
[22].
Distortion of the native oligomeric assembly via V190W and E18W mutations has signifi-
cantly affected the enzyme activity and substrate kinetics. Indeed, forward reaction catalyzed
by the dimeric PfMDH-V190W mutant was interpreted as cooperative with Hill coefficient of
Fig 5. Fig 5 shows specific activity (both forward and reverse reactions) of the wild type PfMDH, E18Q, V190W, E18W mutants, and co-purified WT-
mutant chimeric complex. Specific activity is shown in Units per mg of enzyme (U mg-1). U = μmol of NADH oxidized or (NAD+) reduced per minute. (a & b)
Interference with the native oligomeric state of PfMDH affected substrate kinetics as well as significantly changed specific activity of the mutant species. (b) E18Q
mutant showed increased specific activity for reverse reaction as well as significant substrate inhibition at substrate concentrations above 2.5 mM. (c) At 1.6 mM
malate (reported intracellular substrate concentration [35]) dimeric PfMDH mutants had significantly reduced specific activity towards malate oxidation, while
E18Q mutant activity was not significantly changed compared to WT. No activity could be detected for co-purified PfMDH-WT/V190W chimeric assembly. (d)
At sub-millimolar substrate concentration (0.625 mM oxaloacetate) E18Q mutant showed significantly increased (10x) specific activity, while V190W mutant or
co-purified WT/V190W chimera showed little or no measurable activity, respectively. Interestingly, E18W mutation disrupting AB interface resulted in slightly
increased activity towards oxaloacetate reduction compared to the wild type enzyme.
https://doi.org/10.1371/journal.pone.0195011.g005
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1.5 ± 0.1. Maximal measured specific activity was approx. 0.6 U mg-1 and calculated Khalf was
above 7 mM (Fig 5a). Reverse reaction followed nearly linear trend with maximal measured
activity of 35.2 ± 1.1 U mg-1 at 10 mM oxaloacetate (Fig 5b).
Similarly, disruption of AB interface via E18W mutation resulted in significantly reduced
maximal specific activity measured for forward reaction (approx. 0.17 U mg-1). The reaction
could be interpreted as cooperative with Hill coefficient of 1.45 ± 0.3 (Fig 5a). Reverse reaction
catalyzed by E18W mutant followed Michaelis Menten kinetics with Vmax = 19.3 ± 0.4 U mg-1
and Km = 0.20 ± 0.02 mM (Fig 5b).
Interestingly, E18Q mutation did not significantly change the forward enzyme activity. The
reaction followed Michaelis-Menthen kinetics with slightly lower calculated Km (8.3 ± 0.6 U
mg-1) and reduced Km (2.5 + 0.5 mM), compared to the wild type PfMDH (Fig 5a). In con-
trast, reverse reaction of E18Q was interpreted as cooperative with Hill coefficient of 1.2 ± 0.1
(Fig 5b) at substrate concentrations below 2.5 mM oxaloacetate. Above that concentration
E18Q mutant showed significant substrate inhibition (Fig 5b). Vmax of the reverse reaction
(below 2.5 mM oxaloacetate) increased to 140 ± 6 U mg-1 with significantly lower Khalf of
0.38 ± 0.4 mM.
Oligomeric interfaces can be used to incorporate deactivated mutants into
a PfMDH assembly after recombinant expression
Recombinantly expressed wild-type PfMDH-WT (Strep-tagged) and PfMDH-V190W (His6-
tagged) were expressed separately in E. coli. The lysates were mixed and purified by sequential
streptactin and Ni-NTA-affinity chromatography to isolate the wild-type:mutant complex.
Subsequent Western Blot analysis demonstrated that PfMDH-V190W was able to insert itself
into a pre-formed wild-type PfMDH assembly (Fig 6). Subsequent activity assays demon-
strated that while recombinant wild-type PfMDH displayed both reductive and oxidative
activity, the isolated wild-type:V190W chimera possessed no activity in either direction (Fig 5c
and 5d).
These data support our hypothesis that a properly formed oligomeric assembly is required
for correct catalytic function of PfMDH and that a chimeric assembly can be generated
through introduction of dimeric PfMDH-V190W species to the wild-type tetrameric PfMDH
in vitro. The chimeric PfMDH:PfMDH-V190W has likely a perturbed AC interface and is
shown to be inactive in in vitro activity assays. In conclusion, deactivated oligomeric mutants
can be used in vitro as specific inhibitors of PfMDH activity.
Discussion
The structural data agree with previous findings, in which PfMDH was reported as homo-tet-
ramer in solution [20]. While the majority of MDHs exists in a tetrameric form [24], a number
of homologs from other species have been reported to exist in a dimeric form; and the oligo-
meric assembly of MDH has been suggested to be critical for the enzymatic function [20, 24].
Each monomeric subunit of PfMDH is comprised of 11 beta-sheets and 9 alpha-helixes (Fig
1a). Overall the fold of PfMDH is highly similar to those of previously determined MDHs (see
Results section). While enzymes of the malarial carbon metabolism pathway have been sug-
gested to be promising drug targets, the similarity in fold and associated similarity in position
of the active site residues (Table 2) provides a further demonstration of the difficulties of
validating MDH as a malarial drug target. An insufficiently specific inhibitor of the MDH
active site would almost certainly have significant cross-reactivity with the human MDH
homologs—leading to difficulties in deconvoluting the effect of the MDH inhibitor on the par-
asite in in vivo assays. Unfortunately, genetic approaches in the malarial parasite are non-trivial
Oligomeric interfaces may provide an opportunity to validate drug targets
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and would not necessarily provide a clearer route to the validation of PfMDH as a drug target
[4].
Analysis of the crystal structure of PfMDH showed that AB assembly is highly similar to
that of the active E. coli dimer (Fig 2e). Interestingly, the disruption of the AC interface via
V190W mutation (Fig 3a and 3b) likely breaks the native tetrameric PfMDH assembly into
Fig 6. Fig 6. Western Blot analysis demonstrates the ability of His6-tagged PfMDH-V190W mutants to incorporate into pre-formed native Strep-tagged
oligomeric assembly post-expression. Both proteins were recombinantly expressed and the lysate were mixed and sequentially purified via Ni-NTA and Strep-
tactin chromatography. (Left) Mixed lysate and wild-type PfMDH were first purified via Strep-Tactin (IBA Lifesciences) chromatography and subsequently
analyzed by Western Blot using α-strep antibodies (See Materials and methods), confirming the presence of Strep-tagged PfMDH-WT in both samples. (Right)
Strep-purified samples were further purified via Ni-NTA chromatography. Western Blot with α-His antibodies showed no signal for the wild type sample (as
expected) and confirmed the presence of His6-tagged V190W mutant in co-purified sample.
https://doi.org/10.1371/journal.pone.0195011.g006
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two inactive dimers (Fig 5a and 5d), as supported by SLS (Table 3). Previous attempts to inter-
fere with the native tetrameric assembly of PfMDH have been reported [20]. The authors pro-
posed that disruption of a salt bridge near the AC oligomeric interface (PfMDH-R183A/
R214G) would cause the splitting of the tetramer into an AB dimer, analogous to the dimeric
E. coli MDH. However, while this mutant retained activity, the investigation of the oligomeric
state was performed using size exclusion chromatography rather than direct biophysical mea-
surements. In our study, static light scattering experiments are used to demonstrate the oligo-
meric states of mutants, highlighting the importance of precise biophysical measurements
when estimates of oligomeric state are made. Analysis of our crystal structure of PfMDH also
suggests that PfMDH-R183A/R214G could potentially re-assemble into a tetramer in solution
at least transiently, thereby retaining activity, as no inter-oligomeric clashes were introduced
by these mutations. In contrast, our data demonstrate that the V190W and E18W interface
mutations not only cause the breakdown of the native assembly into dimers (Table 3), but also
make the transient re-formation of the tetramer unlikely due to steric hindrance (Fig 3).
Significantly reduced specific activity (Fig 5), decreased thermal stability (Fig 4) and a shift
to a lower oligomeric state (Table 3) observed for PfMDH-V190W and PfMDH-E18W
mutants suggest that tetrameric assembly of PfMDH is crucial for its catalytic activity,
although the AC and AB interfaces are well separated from the active sites. Furthermore, no
obvious electrostatic connection can be observed between AC interface and the closest active
site. Our kinetic data suggest that this is not as a result of the V190W or E18W mutations cre-
ating misfolded species, as the both mutants were still able to bind cofactor NADH and oxalo-
acetate, although with significantly altered affinities (Table 3). Interestingly, V190W mutation
disrupting AC interface resulted in approx. 3x reduced affinity towards NADH and no appar-
ent change in oxaloacetate binding (Table 3), while E18W showed approx. 10x reduced affinity
towards NADH and 6x increased affinity towards oxaloacetate. These findings suggest differ-
ent control mechanisms, facilitated by the proper formation of AB or AC interface.
As anticipated, stabilization of AB interface with additional hydrogen bonds (E18Q)
improved NADH and oxaloacetate binding approx. 50-fold and 5-fold, respectively (Table 3).
None of the PfMDH variants (including wild type) addressed in this study showed measurable
binding of NAD+ or malate, supporting the assumption that malate-forming reaction is more
favored under standard conditions [24]. Furthermore, no significant thermal stabilization by
NAD+ or malate could be observed by TSA (Table 3). These finding reflect the changes in cata-
lytic activity, observed for all three mutants (Fig 5). Indeed, at intracellular malate concentra-
tion (approx. 1.6 mM), previously estimated by NMR spectroscopy [35], approx. 30x and 190x
reduced specific activity for malate oxidation was observed for V190W and E18W mutants,
respectively (Fig 5c). However, while V190W mutation 4x decreased specific activity for oxalo-
acetate reduction at sub-millimolar oxaloacetate concentration (0.625 mM), E18W mutant
was approx. twice more active, compared to the wild type (Fig 5d). Similarly, in the same con-
ditions E18Q stabilized mutant did not show significant changes in forward activity (malate–
oxaloacetate, Fig 5c), while reverse reaction (oxaloacetate—malate) was 10x more rapid
(Fig 5d).
These data also correlate with previous studies on C. aurantiacus MDH, where mutagenic
alteration of the electrostatic interactions contributing to both AB and AC interfaces lead to
pH-dependent thermal destabilization and up to 4-fold activity loss of resulting mutants com-
pared to the wild type [36]. Furthermore, mutagenic disruption of AB interface in E. coli MDH
using steric clashes resulted in monomeric species and dramatically decreased activity [37].
Our data then show that incorporation of PfMDH-V190W into the wild-type assembly is
possible in vitro, as co-purification using sequential affinity chromatography steps results in a
sample that contains both wild-type and V190W PfMDH species, whereas the control
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experiments did not (Fig 6). No measurable activity could be observed for this chimeric assem-
bly in vitro (Fig 5c and 5d), demonstrating that incorporation of PfMDH-V190W into the
wild-type assemblies can provide a mechanism to specifically target the activity of PfMDH.
This is highly likely to be due to a perturbation of the oligomeric state through the introduc-
tion of a steric clash on the AC interface. Due to the activation effect observed for E18W
mutant at sub-millimolar oxaloacetate concentrations we did not attempt to incorporate
PfMDH-E18W into the native assembly, as the aim of this study was rather specific inhibition.
The ability of PfMDH-V190W to insert itself into the wild-type assembly and perturb its
activity is of key importance for our future experiments, in which we will introduce this
mutant as a recombinantly expressed protein within blood stage parasite cultures in order to
provide validation of PfMDH as a novel potential antimalarial drug target [4, 10]. By using
controlled overexpression of the inactivated mutant within the parasite (using a transfection
technique [38–41]), we propose to achieve overpopulation of the endogenous target protein
and ensure that at least one mutant copy is present in each target protein assembly, thus ren-
dering the target protein inactive. Our approach would potentially bypass the limitations often
associated with conventional drug target validation techniques, such as poor inhibitor trans-
portation, degradation, insufficient specificity or uncertainty in essential gene analysis [4]. The
work presented here also demonstrates that oligomeric state control may have significant
potential in validating other drug targets in the future, both through inhibition and stimulation
of activity.
Materials and methods
Protein production and purification
Cloning, recombinant expression and purification of PfMDH were performed according
to previously reported manuscript[23]. Site-directed mutagenesis was performed using
sequence specific primers and pASK-Iba3-PfMDH-WT plasmid as a template (Table 4).
Resulting plasmids pASK-Iba3-PfMDH-V190W, pASK-Iba3-PfMDH-E18W and pASK-Iba3-
PfMDH-E18Q encoded full length PfMDH with C-teminal His6-tag and V190W, E18W and
Table 4. Primers used in this study.
Primer Sequence
PfMDH cloning for recombinant expression (pASK-IBA3, His6-tag)
IBA3-MDH-s (BsaI, His6) 5’-GCGCGCGGTCTCCAATGACTAAAATTGCCTTAATAGGTAGTGGTC-3’
IBA3-MDH-as (BsaI, His6) 5’-GCGCGCGGTCTCAGCGCTTTAATGATGATGATGATGATGGCCTTTAATTAAGTCGAAAGCTTTTTGTGTG-3’
PfMDH cloning for recombinant expression (pASK-IBA3, Strep-tag)
IBA3-MDH-s (SacII) 5’-ATATCCGCGGATGACTAAAATTGCCTTA-3’
IBA3-MDH-as (NcoI) 5’-AGAGCCATGGCTTTTAATTAAGTCGAAAGC-3’
PfMDH V190W Site-directed mutagenesis primers (pASK-IBA3)
MDH-V190W-s 5’-GATATACATCGGTAAATGGTTGGCCTTTATCTGAATTTGTC-3’
MDH-V190W-as 5’-GACAAATTCAGATAAAGGCCAACCATTTACCGATGTATATC-3’
PfMDH E18W Site-directed mutagenesis primers (pASK-IBA3)
MDH-E18W-s 5’-CAAATCGGAGCAATTGTTGGATGGTTGTGTTTGCTGGAAAATCTTGG-3’
MDH-E18W-as 5’-CCAAGATTTTCCAGCAAACACAACCATCCAACAATTGCTCCGATTTG-3’
PfMDH E18Q Site-directed mutagenesis primers (pASK-IBA3)
MDH-E18Q-s 5’-CAAATCGGAGCAATTGTTGGACAATTGTGTTTGCTGGAAAATCTTGG-3’
MDH-E18Q-as 5’-CCAAGATTTTCCAGCAAACACAATTGTCCAACAATTGCTCCGATTTG-3’
Recognition sites for restriction enzymes used (specified in the primer name) are highlighted in bold. Mutations sites are underlined.
https://doi.org/10.1371/journal.pone.0195011.t004
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E18Q mutations, respectively. All constructs were verified by automated sequencing (Sanger).
The mutant versions of PfMDH were expressed and purified according to the same protocol
as the wild type, with minor modifications.
Briefly, after Ni-NTA purification, PfMDH-V190W, PfMDH-E18W, PfMDH-E18Q and
wild type samples were applied onto S200 10/300 size exclusion column (GE Healthcare), pre-
viously equilibrated with 100 mM Na-Phosphate pH 7.4 and 400 mM NaCl using NGC chro-
matograph (BioRad). The proteins eluted as single peaks with retention volumes of 18.4 mL
(V190W), 17.8 mL (E18W), 16.8 mL (E18Q) and 17 mL (WT).
Thermal Stability Assay (TSA)
TSA assays were performed in 96-well PCR plates (VWR) using SFX96 Real-Time PCR reactor
(BioRad). The protein stability was assayed based on the increased fluorescence of the dye
upon binding to the hydrophobic core of the unfolded protein. SYPRO Orange dye (5000
stock, Invitrogen) was added to the protein sample at 2 mg ml-1 in a 1:500 ratio. The protein
samples were assayed against various buffer systems (pH gradient) as well as buffer compo-
nents [30, 31]. The volume of each sample was 50 μL, the final protein concentration in each
assay was 0.2 mg ml-1 (5,7 μM). Melting curve (in terms of increased fluorescence) of each
sample was plotted against the temperature gradient (293–373 K) and the temperatures of the
inflection points (Tm’s) were used as indicators of the thermal stability of each sample.
Determination of oligomeric state
The oligomeric state of PfMDH wild type and its mutants was determined by static light scat-
tering experiments performed inline with size exclusion chromatography using NGC
(BioRad). PfMDH-WT sample, purified to homogeneity and concentrated to 1.0 mg ml-1, was
injected onto Superdex S75 10/300 (GE Healthcare) size exclusion column in line with Mini-
DAWN TREOS (Wyatt) three angle static light scattering device. The size exclusion column
was previously equilibrated with 100 mM Na-Phospate pH 7.4, and 400 mM NaCl. An inlet fil-
ter was used to prevent big aggregates (>100 nm) from interfering with the measurements.
Static light data was analysed using software provided by the manufacturers (ASTRA 6.1.5.22;
Wyatt Technologies). The PfMDH-WT sample eluted as a single peak and was characterized
as a monodisperse (Mw/Mn = 1.002) tetramer with Mw of 140.5 ± 4.2 kDa (Table 3). The
protein concentration and particle size were calculated based the protein theoretical absor-
bance at 280 nm [Abs 0.1% (1 mg ml-1) = 0.39; http://web.expasy.org/protparam]. Similarly,
PfMDH-E18Q sample was characterized as monodisperse (Mw/Mn = 1.003) tetramer with
Mw of 139.4 ± 0.2 kDa (Table 3). The calculation of the extinction coefficients of PfMDH-WT
and E18Q samples was performed with 10% uncertainty, as the neither WT nor E18Q
sequence contain tryptophan residues.
V190W and E18W samples were characterized as monodisperse dimers (Mw/Mn = 1.003)
with calculated Mw of 70.5 ± 0.3 kDa and 76.6 ± 0.4 kDa, respectively (Table 3).
Activity assays
The kinetic parameters of PfMDH-WT, as well as PfMDH-V190W, PfMDH-E18W and
PfMDH-E18Q mutants were assayed in 100 mM Na-Phosphate pH 7,4, 400 mM NaCl. Spe-
cific activity of PfMDH mutants was assayed based on the increased absorbance of NADH oxi-
dized (NAD+ reduced) at 340 nm and measured as μmol NADH converted per minute by 1
mg of the enzyme. The reactions were performed in 1 ml cuvettes (Sarstedt) at room tempera-
ture using Jasco 650 UV-VIS spectrophotometer (Jasco GmbH). The forward reactions were
performed using 50 nM enzyme pre-incubated in the assay buffer supplemented with 5 mM
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NAD+. The reactions were initiated using decreasing concentrations of DL-malate starting at
10 mM. Similarly, the reverse reaction of the reduction of oxaloacetate was performed by 50
nM of the enzyme in presence of 0.5 mM NADH and initiated by addition of oxaloacetate
(highest concentration 10 mM). All measurements were performed in triplicates. No sponta-
neous NADH oxidation or NAD+ reduction in presence of the high substrate concentrations
and absence of the enzyme was observed.
Microscale Thermophoresis (MST)
MST measurements were performed on a Nanotemper Monolith NT.115 instrument (Nano-
temper Technologies, GmbH) using His-tag fluorescent labeling. Each PfMDH (WT or
mutant) sample, purified to homogeneity, was freshly labeled with the Monolith His-Tag
RED-tris-NTA labeling dye according to the supplied protocol (Nanotemper Technologies,
GmbH). Measurements were performed in 100 mM Na-Phosphate pH 7,4 and 400 mM NaCl
containing 0.05% Tween-20 in standard treated capillaries (MO-K002, Nanotemper Technolo-
gies, GmbH). The final concentrations of either labeled protein in the assay were 50 nM. The
ligands (DL-malate, Oxalacetate, NAD+ and NADH) were titrated in 1:1 dilutions following
manufacturer’s recommendations. All binding reactions were incubated for 10 min at room
temperature followed by centrifugation at 20,000 x g before loading into capillaries. All mea-
surements were performed in triplicates using automatically assigned LED power and medium
MST power, LaserOn time was 30 sec, Laser Off time 5 sec.
Co-purification of PfMDH-WT and PfMDH-V190W
Wild type PfMDH open reading frame was re-cloned into pASK-IBA3 using a modification
of the protocol described in [12, 23] (Table 4). Resulting plasmid encoded full-length
PfMDH-WT with C-terminal Strep-tag. Expression of both Strep-tagged PfMDH-WT and
His6-tagged PfMDH-V190W mutant was performed as described above. The lysates were sep-
arately clarified by centrifugation, mixed and incubated for 2 hours at 277 K [42]. The subse-
quent co-purification from the mixed lysates was performed via the Strep-tactin as well as via
Ni-NTA agarose (IBA Lifesciences, Qiagen).
Co-purified PfMDH-WT and PfMDH-V190W were visualized by western blot using a
monoclonal Strep-tag II antibody (IBA) or anti-His antibody (Pierce, USA) and a secondary
anti-mouse horseradish peroxidase labeled goat antibody (BioRad, Germany) as described in
[42] (Fig 6).
Crystallisation, X-ray data collection and structure determination
PfMDH was purified to homogeneity, concentrated and crystallised as described in [12, 23].
The data collection statistics are shown in Table 1.
Crystal structure of PfMDH was initially solved by molecular replacement using BALBES
software [43] within the CCP4 suite [44] using the data collected on X13 beamline (EMBL,
Hamburg). The PDB model of Cryptosporidium parvum MDH (2HJR) [27] was used as a
search model [28], yielding a clear solution for 16 molecules in the asymmetric unit. The data
from BM14 beamline (ESRF, Grenoble) was subsequently used for molecular replacement
using MOLREP [45] and confirmed the previously identified solution supporting the presence
of four tetrameric PfMDH assemblies in the asymmetric unit. Rebuilding and refinement
were carried out using Coot [46] and Refmac5 [47], respectively. The presence of non-crystal-
lographic symmetry was used as a restraint in refinement at all stages. The final model refined
against data to a resolution of 2.4 Å and has been deposited with the PDB [25] under the
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accession number 5NFR. For more detailed data refinement statistics of PfMDH please refer
to Table 1
Supporting information
S1 Data. The study’s relevant raw MST data.
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